Arboretum Ventures and Johnson & Johnson Innovation led a $78m Series D round in Orasis Pharmaceuticals.

Arboretum Ventures and Johnson & Johnson Innovation, venture capital firms, led a $78m Series D round in Orasis Pharmaceuticals, an ophthalmic pharmaceutical company focused on reshaping vision possibilities, with participation from Catalio Capital Management, Freepoint Capital Group, Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, and Maverick Ventures. "We are pleased to co-lead this financing and to join an experienced syndicate of investors whose collective support is further validation of the market potential for Qlosi. We have high confidence in the Orasis team to successfully launch Qlosi and generate a positive impact on patients' near vision," Paul McCreadie, Arboretum Ventures, Managing Partner.